Medline (NASDAQ:MDLN) Upgraded to “Strong-Buy” at Truist Financial

Truist Financial upgraded shares of Medline (NASDAQ:MDLN) to a strong-buy rating in a research note published on Monday morning,Zacks.com reports.

MDLN has been the subject of several other research reports. Rothschild Redb upgraded shares of Medline to a “hold” rating in a research note on Monday. Leerink Partnrs raised shares of Medline to a “strong-buy” rating in a research report on Monday. Jefferies Financial Group started coverage on shares of Medline in a research note on Monday. They issued a “buy” rating and a $50.00 price objective for the company. Wells Fargo & Company started coverage on Medline in a research note on Monday. They issued an “equal weight” rating and a $42.00 target price on the stock. Finally, Piper Sandler started coverage on Medline in a research report on Monday. They set an “overweight” rating and a $50.00 price target for the company. Eight analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $46.70.

Medline Trading Up 5.4%

Shares of Medline stock opened at $42.72 on Monday. Medline has a 12-month low of $34.89 and a 12-month high of $45.50.

Insider Buying and Selling at Medline

In related news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of Medline stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $28.37, for a total value of $172,727,085.27. Following the sale, the insider owned 4,806,160 shares of the company’s stock, valued at approximately $136,350,759.20. The trade was a 55.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Andrew J. Mills acquired 2,586,206 shares of Medline stock in a transaction on Thursday, December 18th. The shares were purchased at an average cost of $29.00 per share, with a total value of $74,999,974.00. Following the completion of the acquisition, the director owned 2,586,206 shares of the company’s stock, valued at $74,999,974. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information.

Medline News Summary

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Numerous analysts initiated buy/overweight ratings (Barclays, Jefferies, Bank of America, JPMorgan, Wolfe, Mizuho, TD Cowen, Stifel, Piper Sandler, Bernstein, J.P. Morgan, William Blair, Robert W. Baird, Truist). Several targets sit in the $46–$52 range, implying notable upside and helping fuel buying interest. Medline Stock Surges on Post‑IPO Buy Notes
• Positive Sentiment: Jefferies highlighted Medline’s $25 billion supply‑chain scale and gave a “buy” in its coverage debut — a validation of the company’s scale and margin expansion thesis that investors favor. Jefferies Coverage
• Positive Sentiment: Benzinga and other outlets note Medline raised ~$7 billion in its IPO and is being praised for a “prime vendor” model, branded mix shift and margin expansion potential — fundamental reasons analysts cite for buy ratings. Analysts Say Medline Has The Secret Sauce
• Neutral Sentiment: Valuation checks and commentary: several writeups assess MDLN near discounted cash‑flow estimates or “fairly priced” after the recent stability — these limit runaway upside and suggest gains are tied to multiple expansion as much as earnings. Valuation Check
• Neutral Sentiment: Short interest report in the period shows effectively zero/ambiguous data (odd reporting numbers). No clear short‑squeeze signal — treat short‑interest data as non‑contributory for now.
• Negative Sentiment: Some shops initiated neutral/hold ratings with lower targets (BNP Paribas $38 target, Deutsche Bank $40, Wells Fargo $42, Rothschild $42). Those lower targets cap consensus upside and could pressure the stock if follow‑through selling emerges.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.